Navigation Links
Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
Date:4/10/2008

els of the Bicyclolides. The convenience of oral administration and the safety profile of macrolides as a class represent patient and pharmacoeconomic benefits that could be potentially quite significant, making this program a worthwhile endeavor."

About Enanta's Bicyclolide research program

Bicyclolides posses a reengineered back-bone structure of traditional macrolides, whose benefits include the potential for oral and intravenous administration and limited side-effects. The discovery of Bicyclolides' effectiveness against MRSA and VRE infections is part of Enanta's broad antibiotic research program. Enanta has applied several research strategies to develop these new classes of antibiotics, including innovative medicinal chemistry approaches to create novel and proprietary chemical structures. Enanta has applied its chemistry approach to create promising product pipelines and a vast intellectual property estate.

About MRSA

More than 130,000 people each year need hospital care for MRSA, according to the Centers for Disease Control and Prevention. Staphylococcus aureus is a bacterium that can live harmlessly on human skin and is found in the nose of 20 to 40 percent of healthy individuals, but can sometimes cause infections when exposed to broken skin. MRSA is a particular type of the bacteria that has developed resistance to many antibiotics, including methicillin, making it difficult to treat. Currently, the antibiotic drugs typically administered to MRSA patients are intravenous. This method is expensive and inconvenient, especially for those who acquired the infection in the community and must seek hospital treatment for lengthy intravenous treatment.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field. At the heart of Enanta is its commitment to innovative
'/>"/>

SOURCE Enanta Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. NPS Reports Successful GATTEX(TM) Extension Study
9. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
10. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
11. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce the ... and Consultancy focusing on the active pharmaceutical ingredient (API) ... visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s ... – Forecast to 2020 , IQ4I ...
(Date:11/26/2014)... YORK , Nov. 25, 2014  Medtronic,s ... Covidien has been widely discussed in the ... it,s also creating a stronger leading player in ... to Kalorama Information.  The healthcare market research firm ... systems will feature a diverse set of solutions ...
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... , WILMINGTON, Del., Oct. 16 AstraZeneca ... and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) ... familial hypercholesterolemia (HeFH) when diet therapy fails to reduce ... characterized by high LDL cholesterol (the "bad" cholesterol) and ...
... CITY, Oct. 15 Dynatronics Corporation (Nasdaq: DYNT ) ... a letter from Nasdaq stating that the Company has not ... from Nasdaq. , Nasdaq provides the Company an opportunity to ... panel is authorized to grant up to 180 additional calendar ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4
(Date:11/26/2014)... The family foundation of Best Buy founder, ... Research Foundation (Meso Foundation), half of which will be ... Grant Program . The focus area of the Richard ... with organizations that can generate transformational results in education, ... founder and chairman emeritus of Best Buy Co., Inc., ...
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used in ... looks and acts similar to asbestos-induced mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Medicine in Hannover injected 500 lab rats with multi-walled ... developed mesothelioma , how quickly it developed appeared ...
(Date:11/26/2014)... Los Angeles, CA (PRWEB) November 26, 2014 ... Los Angeles orthopedic surgeon Dr. Steven Meier has ... site to offer current and prospective patients an online ... , “We’re really excited to present the new and ... and added features make it easier than ever for ...
(Date:11/26/2014)... 2014 ISI Telemanagement Solutions, Inc., ... been award the 2014 Lync Pioneer Award ... comes as a great honor to ISI, who ... ecosystem. Specifically, ISI offers an integrated collaboration reporting ... communication, including voice, video, Lync IM, and conferencing. ...
(Date:11/26/2014)... 26, 2014 For those with a New ... LES MILLS BODYPUMP™ classes at the University of Colorado ... they've been looking for. The 45- 60 minute classes have ... and Wellness Center fitness club memberships. , LES MILLS BODYPUMP™ ... fast-paced and are aimed at fast results , By ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2
... found that primitive immune systems of fruit flies may ... that immune memory was not possible for insects. ... Medicine could have implications for new ways of developing ... ,The evidence that a fruit fly's immune ...
... Human embryonic stem cells (hESCs) hold great promise for ... provide evidence// that stem cell-derived nerve cells may integrate ... ,This study was conducted by an international collaboration led ... a member of his lab, Jean-Pyo Lee, Ph.D., of ...
... TVs contain possibly hazardous chemicals called polybrominated diphenyl ethers ... of Standards and Technology and the Environmental Protection Agency ... not yet clear how dangerous these PBDEs are, though ... Their structure is strikingly similar to that of PCBs, ...
... risk of prostate cancer amongst Japanese men by as much ... ,"To our knowledge, this is the first prospective study to ... in Japanese, whose intake of soy food is high," wrote ... ,Over half a million news cases of prostate cancer ...
... team of scientists who have achieved a major breakthrough in ... cancer// tumors in humans. ,Anindya Bagchi, along with ... (CSHL), a private research institute in Long Island, New York, ... cells to misbehave and tumors to form. ,The ...
... Unprocessed cocoa is reported to have huge health benefits ... anesthesia//. This was disclosed by Norman Hollenberg, professor of ... suggests that Epicatechin which is found in high levels ... four major and common diseases of the western world ...
Cached Medicine News:Health News:Flies too Have Immune Memory! 2Health News:Flies too Have Immune Memory! 3Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 2Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 3Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 4Health News:Stem Cells Hold Promise for Treating Neurodegenerative Diseases 5Health News:Soy Isoflavones Linked to Lower Prostate Cancer Risk 2
Nitinol Tipless Stone Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
Medicine Products: